GlassScriptPhysician profile
Niranjan G Iyer
NPI 1174583751
$9,121.79
in general payments reported to CMS, 2019-2025
41 companies · $1,887 in 2025
The $1,887 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $951 · 2021: $852 · 2022: $1,457 · 2023: $1,404 · 2024: $1,449 · 2025: $1,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,738.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,966.02 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,699.21 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $620.36 | 2021-2025 | Dupixent |
| Genzyme Corporation | $435.44 | 2019-2025 | |
| Insmed, INC. | $425.32 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $342.49 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $339.55 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.73 | 2020-2024 | Ofev, Stiolto Respimat |
| Mylan Specialty L.P. | $284.06 | 2019-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $246.00 | 2021-2025 | Acthar |
| United Therapeutics Corporation | $207.96 | 2019-2025 | Tyvaso, Tyvaso |
| Pulmonx Corporation | $185.25 | 2023-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Philips North America LLC | $183.20 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Novartis Pharmaceuticals Corporation | $161.58 | 2019-2025 | |
| Verona Pharma, INC. | $157.52 | 2025 | Ohtuvayre |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $155.51 | 2021-2023 | Fetroja |
| Grifols USA, LLC | $142.56 | 2020-2023 | Prolastin-C Liquid |
| Amgen INC. | $140.72 | 2022-2025 | Tezspire, Tavneos |
| Sunovion Pharmaceuticals INC. | $131.41 | 2019-2020 | |
| Abbvie INC. | $113.93 | 2023-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $84.65 | 2023-2024 | Lumryz |
| Viatris Specialty LLC | $78.33 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $76.77 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.06 | 2021-2023 | Hyqvia |
| Merck Sharp & Dohme LLC | $76.04 | 2022-2025 | Winrevair, Recarbrio, Zerbaxa |
| Teva Pharmaceuticals USA, INC. | $57.35 | 2020-2021 | |
| Medtronic, INC. | $46.86 | 2023 | Swiftset |
| Lilly USA, LLC | $45.81 | 2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $42.35 | 2019-2020 | |
| Resmed Corp | $39.16 | 2019-2024 | |
| Genentech USA, INC. | $35.37 | 2019-2020 | |
| Inspire Medical Systems, INC. | $31.36 | 2024 | Inspire |
| Electromed, INC. | $28.08 | 2022 | |
| Inogen, INC. | $27.76 | 2024 | |
| Baxter Healthcare | $24.69 | 2022 | |
| Axsome Therapeutics, INC. | $24.62 | 2024 | Sunosi |
| Gilead Sciences, INC. | $19.21 | 2019 | |
| Allergan, INC. | $17.24 | 2020 | |
| Pfizer INC. | $16.73 | 2021 | |
| Circassia INC. | $15.47 | 2019 | |
| Phadia US INC. | $13.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niranjan Iyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.